A new study has used powerful imaging to reveal a subset of Alzheimer's-associated proteins spreading particularly rapidly.

AbbVie has agreed to pay $1.4 billion to buy Aliada Therapeutics. The acquisition will give AbbVie control of an Alzheimer’s ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

Early data suggest Roche’s antibody may safely and quickly remove amyloid plaque for patients with Alzheimer’s disease, though the mid-stage study has been tied to one death. | Early data suggest ...

The purchase is the latest in a slew of efforts to invest in its neuroscience portfolio as Humira faces generic competition.

Alzheimer's disease, the leading cause of dementia, affects over 55 million people worldwide. The disease is characterized by ...

In a small early trial using a transcranial magnetic stimulation procedure, scientists were able to target a key brain ...

Zizyphi spinosi semen demonstrates neuroprotective effects, improving cognitive function and reducing amyloid and tau pathology in models of aging and dementia.

is recommending the diagnosis of AD be limited to individuals with mild cognitive impairment or dementia and not be applied ...

Drs Pavan Brahmbhatt and Amit Agarwal discuss best practices for managing amyloid-related imaging abnormalities in patients ...

Amyloid fibrils appear in many neurodegenerative diseases, and scientists are eager to understand how they form and spread.

An international team led by researchers at the University of Toronto has developed an efficient and robust system, using the C. elegans nematode, to screen for compounds that can stop the growth of ...